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ABSTRACT
Background and Purpose: Complete surgical resection remains the only curative 
treatment option in locally advanced gastric cancer (GC). Several studies were 
conducted to prevent local recurrence and to increase the chance of cure. The aim of 
this study was to summarize our experience in locally advanced GC patients treated 
with adjuvant chemoradiotherapy (CRT) and to evaluate overall survival (OS), 
disease-free survival (DFS), toxicity rate and compliance to treatment. 
Materials and Methods: Locally advanced GC stage IB-III were included. Adjuvant 
CRT consisted of 45–50.4 Gy (1.8 Gy/day, 5 days/week) with concomitant Macdonald 
regimen (Mcd) or Epirubicin, Cisplatin and 5-Fluorouracil (ECF) scheme. Univariate 
and multivariate analysis of several prognostic factors for OS was conducted. 
Results: Fourty-nine GC patients were treated: 24 received Mcd and 25 received 
ECF. Median follow up was 48 months. Acute grade 3–4 toxicity was observed in  
6 patients. The 2-year and 5-year OS rates were 65.3% and 41.5%, respectively.  
The 2-year and 5-year DFS were 59.2% and 41.2%, respectively. No prognostic 
factors were significantly associated with OS. 
Conclusions: Adjuvant CRT is a feasible strategy in locally advanced GC. It has 
an acceptable toxicity rate and it is able to increase both DFS and OS.
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INTRODUCTION
Complete surgical resection represents the only 
curative treatment option in locally advanced gastric 
cancer (GC). Clinical outcomes are still strongly 
influenced by the high percentage of both local recurrence 
(LR) and distant metastases rates. Approximately 60% 
of GC patients presented locally advanced disease at 
diagnosis. Although a complete tumor resection with 
negative margins (R0) can be achieved in 40–60% of 
these cases, about 70–90% of patients will subsequently 
relapse. An extended lymph node dissection might 
improve local control rate, but its optimal extent remains 
unresolved. 
In order to reduce LR rate and increase cure rate of 
GC patients, several studies have tested different treatment 
strategies after surgery. US Intergroup Study INT-0116 [1] 
was the first large randomized trial that compared adjuvant 
chemoradiotherapy (CRT) versus surgery alone in patients 
with locally advanced disease. This study demonstrated 
a significant impact on progression free survival (PFS) 
and overall survival (OS), although mainly the benefit 
appeared to be derived from a reduction in LR rather than 
in distant metastases rate.
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The aim of this study was to report our data 
concerning patients with locally advanced GC treated with 
adjuvant CRT, in order to analyze treatment compliance, 
toxicity rate and survival outcomes. 
MATERIALS AND METHODS 
Patient selection
Patients with locally advanced GC treated at our 
Department from 2000 to 2011 were retrospectively 
reviewed. All patients were assessed in a multidisciplinary 
clinic board by radiation oncologist, gastrointestinal 
surgeon and medical oncologist. The study was approved 
by the Institutional Reviewed Board and patients signed 
an informed consent.
Eligibility criteria included histologically confirmed 
gastric adenocarcinoma; stage IB-III disease; lack of 
involvement of esophagus; no distant metastases; a 
performance status of 0–2 according to the criteria of 
the Eastern Cooperative Oncology Group (ECOG); age 
greater than 18 years; adequate liver, renal and bone-
marrow function. 
Treatment
All patients underwent surgery: gastrectomy or 
gastric resection with limited (D1) or extended (D2) 
lymph node dissection was performed at least 3 months 
before starting adjuvant CRT. Prior to CRT, all patients 
were subjected to post-surgical revaluation with clinical 
examination and total-body computed tomography scan.
All patients were treated with a concomitant 
adjuvant treatment.
Radiotherapy (RT) consisted of 45 Gy in 
25 fractions (1.8 Gy/fraction, 5 days/week). In patients 
with resection margin microscopically involved (R1) the 
total dose was 50.4 Gy, with boost of 5.4 Gy. 
From 2000 to 2004, external beam RT was delivered 
with a two-dimensional technique (2DRT) with anterior-
posterior opposing fields and in the next years using three-
dimensional RT (3DRT) with a multiple field technique. 
The planning target volume (PTV) included tumor 
bed, as defined by preoperative imaging, residual stomach 
or anastomosis site with a safety margin of at least 2 cm 
and regional lymph nodes, based on the location of the 
primary tumor and the type of surgical procedure carried 
out. Regional lymph nodes included the perigastric, 
the periesophageal, the celiac axis, the para-aortic, the 
hepato-duodenal and pancreatic-duodenal lymph nodes as 
well as the nodes along the splenic artery to the splenic 
hilum and along the hepatic artery to the hepatic hilum. 
The dose planning for PTV and organs at risk (OAR) 
were performed according to the ICRU 50 [2] and 62 [3] 
guidelines.
A central venous access was placed for the 
administration of concomitant chemotherapy (CT). 
According to medical oncologist, two CT regimens 
were used: Macdonald scheme (Mcd) and Epirubicin, 
Cisplatin and 5-Fluorouracil scheme (ECF). Mcd 
consisted of continuous infusion of 5-Fluorouracil (5-FU, 
425 mg/mq per day) plus Leucovorin (LV, 20 mg/mq 
per day) for 5 days, given every 3 weeks for two cycles, 
followed by continuous infusion of 5-FU (400/mg/mq/day) 
and LV (20 mg/mq/day) on days 1–4 and 23–25 during 
concomitant RT, and an additional cycles of 5-FU 
(425 mg/mq/day) and LV (20 mg/mq/day). The ECF 
scheme consisted of Epirubicin (50 mg/mq), Cisplatin 
(60 mg/mq) and 5-FU (200 mg/mq/day) before (1 cycle) 
and after (2 cycle) concurrent CRT.
Toxicity
During CRT patients were evaluated daily. Toxicity 
was graded according to the Common Terminology Criteria 
for Adverse Events (NCI-CTCAE), version 4.0 [4].  
Follow-up
After adjuvant therapy, post-treatment surveillance 
was performed every 3 months for the first 2 years, every 
6 months for the subsequent 3 years and then annually. 
Follow-up consisted of physical examination, a complete 
blood cell count, liver and renal function tests, level of 
tumour markers (CEA, Ca 19.9), abdominal ultrasound, 
total body computed tomography scan and PET/CT as 
clinically indicated.
Statistical analysis
 Standard descriptive statistics were used to evaluate 
the distribution of each factor. Continuous data were given 
as median (range), and categorical data as the number of 
observations and ratios. 
OS and DFS were calculated in months from the 
date of the end of treatment to the first event, including 
date of the last follow-up or death (OS), and/or relapse 
(DFS).
OS and DFS were estimated using the Kaplan–
Meier method and survival curves were compared using 
the log-rank test. 
The following variables were investigated: sex 
(male versus female), age in years at diagnosis (< 65 
versus ≥ 65), tumor grading (G1-2 versus G3), tumor site 
(cardia versus body-pylorus), CT regimen (Mcd versus 
ECF) and type of lymph node dissection (D1 versus 
D2). Variables associated with a p-value < 0.25 would 
be included in a multivariate survival analysis performed 
using Cox proportional hazard model. All reported 
p values are two-sided, and p-values lower than 0.05 were 
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considered significant. Statistical analysis was performed 
using RStudio-0.98.1091 software.
RESULTS
Baseline characteristics
 Between 2000 and 2011, 49 locally advanced GC 
patients were treated at our institution. Baseline patient 
and tumour characteristics are shown in Table 1. Median 
age was 59 years (35–78) and 23 patients (46.9%) were 
male. Median follow up was 48 months (3–129). 
Thirty-six patients (73.5%) received D2 lymph node 
dissection and 13 patients (26.5%) received D1 dissection. 
Patients with R1 surgical margins were 16 (32.6%). 
Twenty-four patients (49%) received Mcd regimen 
and 25 patients (51%) received ECF scheme. All patients 
completed RT as planned: 45 Gy in 33 patients (67.4%); 
50.4 Gy in 16 patients (32.6%). 
Acute grade 3–4 toxicities were observed in 
6 patients (12.1%) (Table 2). No patients required hospital 
recovery for acute toxicity during adjuvant treatment.
Overall, 46 patients (94%) receive full dose of CT. 
Three patients (6%) were unable to complete CT: 1 patient 
due to G3 gastrointestinal toxicity and 2 patients due to 
reduced compliance. No patient had treatment interruption 
for progressive disease.
Overall survival and disease-free survival 
analysis
Overall, median OS and DFS were 46 months and 
39 months, respectively. Thirty-one patients (63.3%) 
had died. The 2-year and 5-year OS rates for the entire 
population were 65.3% (95% CI 0.503–0.768) and 41.5% 
(95% CI 0.268–0.545), respectively. The 2-year and 5-year 
DFS were 59.2% (95% CI 0.442–0.714) and 41.2% (95% 
0.271–0.548), respectively. The prognostic analysis is 
shown in Table 3. No prognostic factors were significantly 
associated with OS. 
Overall, 30 patients (61.2%) relapsed. Most of these 
patients (n = 28, 93.3%) had distant metastases, in 8 cases 
(28.6%) associated with loco-regional failures. Only 
2 patients (6.7%) had local recurrences and both within the 
first year after the end of treatment (1-year DFS = 69.4%, 
95% CI 0.544–0.803). 
Subgroup survival analysis
The 2-year OS for Mcd group versus ECF group 
was 70.8% (95% CI 0.484–0.849) versus 60.0% (95% CI 
0.384–0.761); the 5-year OS for Mcd group versus ECF 
group was 48.7% (95% CI 0.276–0.669) versus 34.3% 
(95% CI 0.166–0.528) (p = 0.568) (Figure 1).
The 2-year and 5-year DFS in Mcd group versus 
ECF group were 66.7% (95% CI 0.443–0.817) versus 52% 
(95% CI 0.313–0.692) and 48.9% (95% CI 0.278–0.67) 
versus 33.4% (95% CI 0.156–0.523) (p = 0.404), 
respectively (Figure 2). 
DISCUSSION
GC is usually diagnosed in locally advanced stage. 
Prognosis is poor, with 5-year OS of 5–20% [5]. Surgery 
is considered the current standard recommendation. 
However, survival rates remain quite low despite tumor 
curative resection and therefore different adjuvant 
strategies were extensively tested. At present, no standard 
CT regimens have been defined and the role of adjuvant 
RT after an adequate lymph node dissection is unclear. 
It is well established that survival outcomes 
significantly differ between Asian and Western cohort 
studies [6]. Thus it is difficult to compare their results 
mainly due to differences in disease natural history, 
diagnostic approach and treatment strategy. 
For instance, Japanese and other Asian surgeons 
routinely perform a D2 lymph node dissection to remove 
the nodes along the mains branches of the celiac axis. 
Whereas the vast majority of Western surgeons perform 
a D1 dissection, including only lymph nodes close to 
surgical stomach bed, in order to reduce morbidity and 
mortality rates. 
Both Dutch trial [7] and MRC (Medical Research 
Council) trial [8] registered high postoperative 
complications and mortality rates following D2 dissection 
without a significant improvement in survival outcomes 
compared to D1 dissection. The update data of Dutch 
trial showed a lower LR rate and cancer-related deaths 
in D2 lymphadenectomy [9]. However, it should be 
emphasized that in more advanced stages even with an 
adequate lymphadenectomy the results of surgery in 
Western patients are still unsatisfactory [10]. In this setting 
of patients, additional treatments should be planned to 
improve patients’ long-term survival.
Based on MAGIC trial results [11], nowadays 
the neoadjuvant approach is recommended. The aim of 
neoadjuvant CT (NACT) is to downstage and downsize 
primary tumor and to treat potential micro-metastasis.
Different studies demonstrated a significant 
improvement in OS rates of NACT versus surgery alone. 
Schuhmacher et al. [12] reported that NACT improved R0 
resection rate without impact on OS rate. Similarly, Stahl 
et al. [13] showed a higher rate of complete responders 
and Van Hagen et al. [14] reported an improved OS. A 
recent meta-analysis of 1820 patients with advanced GC 
confirmed NACT survival benefit (OR: 1.32; 95% CI: 
1.07–1.64; p < 0.01), 3-year PFS (OR: 1.85; 95% CI: 
1.39–2.46; p < 0.0001), tumor down-staging rate (OR: 
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Table 2: Toxicity grade sec CTCAE V4.0
Number of patients (%)
Toxicity Grade 2 Grade 3 Grade G4
Gastrointestinal 3 (6) 1 (2) -
Weight loss 3 (6) 2 (4) 1 (2)
Thrombocytopenia 2 (4) - -
Anaemia 2 (4) 1 (2) -
Mucositis 2 (4) 1 (2) -
Neurological 2 (4) - -
Skin reaction 1 (2) - -
Table 1: Baseline patients’ and tumours’ characteristics
Patients’ characteristic N (%) Tumours’ characteristic N (%)
Sex: Adenocarcinoma 49 (100)
 Male 23 (46.9)
 Female 26 (53.1)
Age: Grading:
 Median 59 G2 12 (24.5)
 Range 35–78 G3 35 (71.4)
G4 2 (4.1)
PS ECOG: Anatomical Site:
 0 19 (38.8) Cardia 22 (45)
 1 24 (49) Body/pylorus 27 (55)
 2 6 (12.2)
Surgery: pT Stage:
 Gastrectomy 30 (61.2) pT1 3 (6.1)
 Gastroresection: 19 (38.7) pT2 5 (10.2)
  Billroth I 3 (15.8) pT2a 1 (2)
  Billroth II 16 (84.2) pT2b 18 (36.7)
pT3 15 (30.6)
pT4 7 (14.3)
Lymphadenectomy: pN Stage:
 D1 13 (26.5) N0 6 (12.2)
 D2 36 (73.5) N1 19 (38.8)
N2 15 (30.6)
N3 9 (18.4)
pM Stage:
Mx 46 (93.9)
M0 3 (6.1)
TNM:
IB 7 (14.3)
II 10 (20.4)
IIIA 17 (34.7)
IIIB 8 (16.3)
  IV 7 (14.3)
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1.71; 95% CI: 1.26–2.33; p < 0.0006) and R0 resection 
rate (OR: 1.38; 95% CI: 1.08–1.78; p < 0.01) [15]. 
The aim of this study was to investigate OS, DFS, 
toxicity rate and treatment compliance in patients with 
locally advanced GC treated with postoperative CRT. Two 
CT regimens were analysed: Mcd and ECF. Mcd group 
achieved higher DFS and OS rates then ECF group. 
In the Intergroup trial INT-0116 [1] a significant 
OS improvement resulted in those patients who received 
adjuvant CRT versus surgery alone. Authors reported that 
19% of patients in the CRT arm had LR versus 29% in the 
control arm. However, the high LR rate should be related 
to limited lymph node dissection. Our median OS in Mcd 
regimen was higher than INT 0116 trial (46 months versus 
Table 3: Univariate and multivariate analysis of prognostic factor for overall survival
Univariate analysis Multivariate analysis
Prognostic factor HR (95% CI) p value HR (95% CI) p value
Sex (male vs female) 0.59 (0.82–3.42) 0.15 0.55 (0.88–3.79) 0.10
Age (< 65 vs ≥ 65) 1.10 (0.43–1.88) 0.79
Grading (G1-2 vs G3) 1.59 (0.28–1.41) 0.25 1.81 (0.24–1.27) 0.16
Tumour location (cardia vs body/pylorus) 0.95 (0.52–2.12) 0.89
Chemotherapy regimen (Mcd vs ECF) 0.81 (0.59–2.54) 0.56
Lymph node dissection (D1 vs D2) 0.78 (0.54–2.96) 0.57   
Mcd: Macdonald.
Figure 1: Overall survival in Macdonald (Mcd) patients and ECF patients.
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36 months). It should be noted that 73.5% of our patients 
underwent D2 dissection versus 10% in the INT 0116 trial. 
In our study, all patients with D1 dissection developed LR.
In the Korean ARTIST study [16], after gastrectomy 
with D2 dissection, patients were randomized to adjuvant 
CT or adjuvant CRT. There were no differences in DFS 
and OS between the two groups, but a subgroup analysis 
showed an improvement in DFS in the CRT group 
(p = 0.0365). 
The European CRITICS trial [17] evaluated the 
clinical outcome for adjuvant CT versus adjuvant CRT 
after 3 cycles of NACT. The results are expected.
Our patients completed planned RT and 94% of 
patients received CT at full dose. The optimal toxicity 
rate (mainly gastrointestinal) was probably related 
to modern RT technique. In fact, since 2004, RT was 
delivered with 3DRT that allows to conform the radiation 
dose on the PTV and to reduce the volume and the dose 
to the surrounding OARs. Whereas, literature data still 
refers to a 2DRT technique, using two fields AP and PA. 
Maybe, in our study, premedication to CRT, including 
metoclopramide, ondansetron and dexamethasone, 
contributed to lower toxicity rates, too.
In the INT 0116 trial, 36% of patients did not 
complete the treatment, mainly due to G3-4 toxicities 
(17% of cases). In a retrospective study of Kundel 
et al. [18] higher toxicity rates were registered: 46.4% 
of patients presented severe adverse events, 32% were 
hospitalized and 1.8% died. 
In this analysis, sex, age, tumor grading, tumor 
site, CT regimen and type of lymph node dissection 
were no significantly associated with OS. However, in 
several retrospective studies some prognostic factors 
were demonstrated [19–21]. N-category and N-ratio 
interaction, perineural invasion and extended resections 
were prognostic factors for survival in GC patients treated 
with D2 dissection in a retrospective study by Costa 
et al. [21]. Therefore, it seems that a category of patients 
may benefit from an intensified therapy. This setting of 
patients may be treated with NACT, surgery and adjuvant 
treatment, while other types of patients may benefit from 
a radical surgery followed by adjuvant therapy. 
In conclusion, adjuvant CRT was a feasible strategy 
in locally advanced GC. It had an acceptable toxicity rate 
and it was able to increase both DFS and OS, even after 
extended lymph node dissection. Modern 3DRT reduced 
toxicity effects. 
As a future perspective, it is desirable to find 
prognostic factors to select patients in order to provide a 
personalized therapy. 
Figure 2: Disease free survival in Macdonald (Mcd) patients and ECF patients.
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